文献速递头颈部肿瘤放疗放疗物理与技术

EORTC 1420 试验放疗质量保证基准病例流程结果

Quality assurance of radiotherapy in the ongoing EORTC 1420 "Best of" trial for early stage oropharyngeal, supraglottic and hypopharyngeal carcinoma: results of the benchmark case procedure.
PubMed 文献 · Radiat Oncol · 2021-05-01

该研究分析了EORTC 1420 III期试验中放疗质量保证的基准病例流程,比较参与中心提交的放疗体积和计划与专家金标准。结果显示65%机构需多次提交才能通过质量保证,危及器官体积勾画是53%病例被拒的原因,重提交后12个危及器官中5个的观察者间变异可改善超过10mm,但关键危及器官的最终观察者间变异仍显著。

要点

  • 65%机构需多次提交才能达到放疗质量保证 clearance。
  • 53%病例因危及器官体积勾画被拒。
  • 重提交后部分危及器官观察者间变异改善,但关键结构仍显著。

核心结论

  • 基准病例流程可识别非共通危及器官和靶区勾画错误为主要偏差来源,并在相当数量病例中降低观察者间变异。

研究设计与样本

  • 前瞻性III期试验EORTC 1420的基准病例流程分析,分析参与中心提交的放疗体积和计划,与金标准专家勾画和剂量分布比较,并进行描述性方案偏差分析。

主要发现

  • 65%(23/35)机构需要超过一次提交才能达到质量保证 clearance。
  • 危及器官体积勾画是53%(40/76)病例被拒的原因。
  • 重提交后,12个危及器官中5个的观察者间变异(平均Hausdorff距离)改善超过10mm。
  • 选择0.7(平均Sorensen-Dice相似指数)和15mm(平均Hausdorff距离)阈值时,关键危及器官勾画的最终观察者间变异仍显著。

关键数值与推荐

  • 采用平均Sorensen-Dice相似指数(mDSI)和平均Hausdorff距离(mHD)评估观察者间变异。
  • 选择任意阈值0.7(mDSI)和15mm(mHD)评估关键危及器官最终观察者间变异。

临床怎么用

  • 在头颈部放疗前瞻性试验中,应实施基准病例流程以识别和纠正勾画偏差,尤其关注非共通危及器官和靶区。

局限性

  • 基准病例流程涉及大量资源,未来分析应全面评估对患者临床结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The current phase III EORTC 1420 Best-of trial (NCT02984410) compares the swallowing function after transoral surgery versus intensity modulated radiotherapy (RT) in patients with early-stage carcinoma of the oropharynx, supraglottis and hypopharynx. We report the analysis of the Benchmark Case (BC) procedures before patient recruitment with special attention to dysphagia/aspiration related structures (DARS). MATERIALS AND METHODS: Submitted RT volumes and plans from participating centers were analyzed and compared against the gold-standard expert delineations and dose distributions. Descriptive analysis of protocol deviations was conducted. Mean Sorensen-Dice similarity index (mDSI) and Hausdorff distance (mHD) were applied to evaluate the inter-observer variability (IOV). RESULTS: 65% (23/35) of the institutions needed more than one submission to achieve Quality assurance (RTQA) clearance. OAR volume delineations were the cause for rejection in 53% (40/76) of cases. IOV could be improved in 5 out of 12 OARs by more than 10 mm after resubmission (mHD). Despite this, final IOV for critical OARs in delineation remained significant among DARS by choosing an aleatory threshold of 0.7 (mDSI) and 15 mm (mHD). CONCLUSIONS: This is to our knowledge the largest BC analysis among Head and neck RTQA programs performed in the framework of a prospective trial. Benchmarking identified non-common OARs and target delineations errors as the main source of deviations and IOV could be reduced in a significant number of cases after this process. Due to the substantial resources involved with benchmarking, future benchmark analyses should assess fully the impact on patients' clinical outcome.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Stelmes JJ, Vu E, Grégoire V, et al. Quality assurance of radiotherapy in the ongoing EORTC 1420 "Best of" trial for early stage oropharyngeal, supraglottic and hypopharyngeal carcinoma: results of the benchmark case procedure. Radiat Oncol. 2021. PMID: 33933118. doi:10.1186/s13014-021-01809-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。